ATE552888T1 - Elastasehemmer bei leukämie - Google Patents

Elastasehemmer bei leukämie

Info

Publication number
ATE552888T1
ATE552888T1 AT05764348T AT05764348T ATE552888T1 AT E552888 T1 ATE552888 T1 AT E552888T1 AT 05764348 T AT05764348 T AT 05764348T AT 05764348 T AT05764348 T AT 05764348T AT E552888 T1 ATE552888 T1 AT E552888T1
Authority
AT
Austria
Prior art keywords
leukemia
inhibitors
elastic
treatment
aml
Prior art date
Application number
AT05764348T
Other languages
English (en)
Inventor
Tsvee Lapidot
Sigal Tavor
Isabelle Petit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE552888T1 publication Critical patent/ATE552888T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05764348T 2004-08-10 2005-08-04 Elastasehemmer bei leukämie ATE552888T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL163453A IL163453A0 (en) 2004-08-10 2004-08-10 Enzyme inhibitor in leukemia
PCT/IL2005/000840 WO2006016353A2 (en) 2004-08-10 2005-08-04 Elastase inhibitor in leukemia

Publications (1)

Publication Number Publication Date
ATE552888T1 true ATE552888T1 (de) 2012-04-15

Family

ID=35124397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05764348T ATE552888T1 (de) 2004-08-10 2005-08-04 Elastasehemmer bei leukämie

Country Status (10)

Country Link
US (1) US20090232793A1 (de)
EP (1) EP1781377B1 (de)
JP (1) JP4950885B2 (de)
AT (1) ATE552888T1 (de)
AU (1) AU2005270821B2 (de)
CA (1) CA2576419C (de)
ES (1) ES2381195T3 (de)
IL (2) IL163453A0 (de)
NO (1) NO20071330L (de)
WO (1) WO2006016353A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
WO2017049002A1 (en) * 2015-09-15 2017-03-23 Massachusetts Institute Of Technology A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system
CN116087338B (zh) * 2023-04-10 2023-07-14 四川省地质矿产勘查开发局一0六地质队 一种岩石脆性破坏前兆指标的构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
GB9307555D0 (en) * 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
WO1997039028A1 (en) * 1996-04-12 1997-10-23 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
US5760027A (en) * 1996-12-06 1998-06-02 Research Corporation Technologies, Inc. Use of 7-alkylidene cephalosporins to inhibit elastase activity
GB9719172D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
WO2002094864A2 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
WO2004041115A2 (en) * 2002-06-14 2004-05-21 North Shore - Long Island Jewish Research Institute Novel human elastases and stress urinary incontinence

Also Published As

Publication number Publication date
US20090232793A1 (en) 2009-09-17
CA2576419C (en) 2013-07-02
WO2006016353A2 (en) 2006-02-16
IL181183A (en) 2010-12-30
WO2006016353A3 (en) 2006-07-13
EP1781377A2 (de) 2007-05-09
AU2005270821A1 (en) 2006-02-16
IL163453A0 (en) 2009-02-11
JP4950885B2 (ja) 2012-06-13
CA2576419A1 (en) 2006-02-16
EP1781377B1 (de) 2012-04-11
AU2005270821B2 (en) 2011-06-02
JP2008509903A (ja) 2008-04-03
ES2381195T3 (es) 2012-05-24
IL181183A0 (en) 2007-07-04
NO20071330L (no) 2007-03-12

Similar Documents

Publication Publication Date Title
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
EP1812049A4 (de) Kallikrein-hemmer und ihre verwendungen
EP1740183B8 (de) Neue verwendung von pde5-hemmern
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
MA28707B1 (fr) Utilisation de 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines substituees lors du traitement de nausees et de vomissements
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
DK1685150T3 (da) Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
NO20081292L (no) Pentasykliske kinaseinhibitorer
ES2377881T3 (es) Inhibidores de Glepp-1 en el tratamiento de trastornos autoinmunes y/o inflamatorios
ATE552888T1 (de) Elastasehemmer bei leukämie
EP1858509A4 (de) Neue cathepsin-c-hemmer und ihre verwendung
SG149070A1 (en) Non-nucleotide reverse transcriptase inhibitors
DE50309647D1 (de) Ng fibrotischer erkrankungen
ECSP055715A (es) Utilizacion de pirimetanilo en patogenos resistentes
DK1358182T3 (da) Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer
TW200605895A (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor
AU311455S (en) Cycle mudguard
DOP2005000121A (es) Compuesto farmaceutico
ATE482198T1 (de) Sitamaquintosylat zur behandlung von leishmaniase
AU311456S (en) Cycle mudguard
WO2008024734A3 (en) Use of pkc inhibitors in particular indolylmaleimide derivatives in ocular diseases
UY3516Q (es) Inhalador-rotahaler-m
ES2355499T8 (es) Nitrosofenoles y c-nitrosoanilinas como inhibidores de polimerización.